Global medical technology (medtech) companies are entering a period of accelerated structural change, driven by pricing reforms in China, the migration of procedures to outpatient settings, supply chain pressures, the rise of GLP-1 therapies, and the growing importance of platform-based technologies. These forces are reshaping how companies compete, where growth occurs, and how value is delivered across the healthcare ecosystem.

According to a new report from Clarivate, a global provider of transformative intelligence, these five medtech trends stand out in 2026.

China's Volume-Based Procurement Redefines Market Economics

The expansion of mainland China's national volume-based procurement (VBP) program has emerged as one of the most consequential shifts in global medical device pricing. Initially designed to improve patient access and reduce device costs, the program has evolved into a powerful market-structuring mechanism. The latest rules introduce more sophisticated anchor-price logic, deeper price compression, and allocation systems that support domestic manufacturers.

For multinational companies, VBP is no longer a localized policy. It now influences expectations around price, volume, and competitive positioning in markets far beyond China. The program is accelerating domestic innovation and forcing international players to rethink their portfolio strategies and participation models in one of the world's largest medtech markets.

Outpatient and Ambulatory Surgery Centers Gain Prominence

The shift of procedures from hospitals to outpatient settings continues to accelerate. The U.S. Centers for Medicare & Medicaid Services (CMS) 2026 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System Final Rule reinforces this trend by expanding the ASC Covered Procedure List and phasing out the inpatient-only list. This opens the door for higher-acuity procedures such as cardiac ablation to move into lower-cost settings when clinically appropriate.

This migration builds on established patterns in orthopedics, general surgery, and other specialties where ASCs have become critical to growth strategies. For medtech manufacturers, adapting commercial models, economic value propositions, and product designs to diverse sites of service is becoming essential.

Trade Pressures Reshape Manufacturing Strategy

Supply chain resilience is now a strategic imperative for medtech companies. Tariff exposure, geopolitical factors, and fluctuating material costs are challenging long-standing assumptions about where and how devices should be produced. Companies are responding by diversifying sourcing, re-evaluating business strategies, and pursuing more flexible multi-region manufacturing footprints.

Larger manufacturers are leveraging scale, integration, and technology investment to buffer against global volatility, a trend that could reshape competitive dynamics across categories. Cost structures, supplier concentration, and manufacturing geography are increasingly influencing competitive advantage alongside product performance.

GLP-1 Therapies Alter Patient Behavior and Care Pathways

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists is changing how patients and clinicians approach weight management and related comorbidities. While bariatric surgery remains the most effective intervention for substantial weight loss, GLP-1s have expanded in popularity, altering referral patterns and influencing demand across adjacent medtech categories.

The impact varies by procedure type. Some bariatric procedures face sharper volume pressure, while downstream effects — in diabetes care, sleep apnea, and cardiovascular monitoring — are only beginning to emerge. This reflects a broader shift in metabolic disease management with ripple effects across multiple device markets and clinical pathways.

Enabling Technologies Drive Platform-Based Competition

Enabling technologies, including robotics, imaging, navigation, and digital workflow software, are shifting from procedural adjuncts to central components of integrated ecosystems. Companies are investing in platform architectures that anchor entire service lines, strengthen customer relationships, and unlock data-driven value propositions. Emerging open-platform systems are also expanding flexibility and creating new competitive dynamics.

Platform-based competition is redefining how medtech companies deliver value, engage customers, and build long-term strategic advantage.

International Context and Global Relevance

These trends are not isolated. China's VBP program is a key element of the country's efforts to contain healthcare costs while promoting domestic innovation. The U.S. shift to outpatient care reflects broader global efforts to reduce healthcare spending and improve efficiency. Trade pressures are part of a wider recalculation of global supply chains across industries. GLP-1 adoption is a worldwide phenomenon with major implications for chronic disease management. And platform-based technologies are becoming central to modern healthcare delivery in many advanced economies.

Together, these forces highlight how medtech companies must operate in a more integrated, data-driven, and cost-conscious global environment. International cooperation, regulatory alignment, and innovation policy will shape how the industry evolves.

Analysis and Implications

According to Clarivate's analysts, the medtech industry's response to these trends will determine future market leadership. The report emphasizes that understanding pricing dynamics, regulatory changes, and technology integration is essential for companies seeking to maintain competitiveness.

The analysis suggests that multinational companies need to adopt more flexible operating models, invest in local capabilities where required, and embrace open platforms that enable interoperability. The shift to outpatient care requires new commercial approaches, while supply chain diversification is a defense against geopolitical risk.

These developments also present opportunities for companies that can adapt quickly. Domestic manufacturers in China may benefit from VBP policies, while global players can find growth in premium segments and advanced technologies.

Future Developments

Over the next two to five years, the report's findings point to continued evolution rather than sudden disruption. Expect:

• Further expansion of China's VBP program into new device categories, with deeper price cuts and greater domestic substitution.
• Continued growth of ASCs and outpatient care, supported by policy changes and technological advances.
• Increasing investment in resilient supply chains, with multi-region manufacturing becoming the norm.
• Growing integration of GLP-1 therapies into standard metabolic care, with downstream effects on medical devices.
• Accelerated adoption of robotic, imaging, and digital platforms that enable data-rich, outcome-based service delivery.

These trends will likely reinforce the importance of innovation, regulatory agility, and international collaboration in the medtech sector.

Conclusion

The medtech industry is at a pivotal juncture. Structural forces across pricing, care delivery, supply chains, clinical pathways, and technology are reshaping the competitive landscape. Companies that understand and respond to these trends — through strategic portfolio management, operational flexibility, and platform-based innovation — will be better positioned for sustainable growth in the global marketplace.

As the report from Clarivate underscores, the medtech trends of 2026 are not isolated developments but interconnected signals of a broader transformation in global healthcare.